Healthcare / BiotechnologyVienna
$2.84
+0.01 (+0.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-4.3M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$70M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-47.1%
↓Gross Margin
-7207.5%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+44.2%
FCF CAGR
—
FCF margin
-19997.8%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $93000.0 · net income $-16.5M · FCF $-18.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $93000.00 | $93000.00 | $118000.00 | $24000.00 | $31000.00 |
| Net Income | $-16.5M | $-16.5M | $-12.8M | $-7.6M | $-2.0M |
| EBITDA | $-15.8M | $-15.8M | $2.5M | $-5.9M | $-665000.00 |
| EPS | — | — | -0.52 | -0.31 | -0.08 |
| Gross Margin | -7207.5% | -7207.5% | -3050.8% | 19666.7% | 12809.7% |
| Operating Margin | -21059.1% | -21059.1% | -14899.2% | -25670.8% | -7019.4% |
| Net Margin | -17753.8% | -17753.8% | -10883.9% | -31829.2% | -6325.8% |
| Balance Sheet | |||||
| Current Ratio | 2.15 | 2.15 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-18.6M | $-18.6M | $-4.3M | $-2.8M | $-6.2M |
| Returns | |||||
| ROE | -47.1% | -47.1% | -26.0% | -15.8% | -5.1% |
| Valuation | |||||
| P/B | 2.01 | 2.01 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -21.2% | -21.2% | 391.7% | -22.6% | — |
| EPS Growth | — | — | -68.8% | -289.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.52 → n/d
Residual
+8.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.